Source: Annual Congress 2003 - Advances in our understanding of corticosteroids in the treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. D. Smith, J. Cowan, D. R. Taylor (Dunedin, New Zealand). Optimising inhaled corticosteroid (ICS) dose using exhaled nitric oxide (eNO) measurements. Eur Respir J 2003; 22: Suppl. 45, 342

Member's Comments

No comment yet.

Related content which might interest you: Fractional exhaled nitric oxide (FeNO) could be a good predictor for the effectiveness of inhaled corticosteroid (ICS) in patients with COPD Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Dose response to inhaled fluticasone/salmeterol measured with extended exhaled nitric oxide in refractory asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Exhaled nitric oxide and inhaled corticosteroid dose reduction in asthma: a cohort study Source: Eur Respir J 2014; 44: 1705-1707 Year: 2014 Effect of inhaled steroids and long-acting β2 agonists on exhaled nitric oxide (eNO) in asthmatic children Source: Eur Respir J 2004; 24: Suppl. 48, 270s Year: 2004 Utility of fractional exhaled nitric oxide (FeNO) in assessing asthma control following inhaled corticosteroid treatment Source: International Congress 2016 – Assessing lower airway inflammation with different tools Year: 2016 Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children Source: Eur Respir J 2002; 20: 630-634 Year: 2002 Fractional exhaled nitric oxide (FeNO) suppression with directly observed inhaled corticosteroid therapy: does it make a difference to patient outcomes? Source: International Congress 2018 – Clinical and functional monitoring in airway disease Year: 2018 Benefit of inhaled corticosteroids (ICS) in asthmatic patients with bronchial hyperresponsiveness (BHR) to mannitol and low fractional exhaled nitric oxide (FeNO) levels Source: International Congress 2017 – Monitoring asthma control Year: 2017 Changes of exhaled nitric oxide during steroid treatment of childhood asthma Source: Eur Respir J 2002; 19: 1015-1019 Year: 2002 Diagnosing asthma using exhaled nitric oxide (eNO) measurements Source: Annual Congress 2003 - Recognition, management and assessment of asthma including severe asthma Year: 2003 Predicting response to corticosteroid in COPD using exhaled nitric oxide Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Stability of exhaled nitric oxide (FENO) in patients with severe, steroid-dependent asthma Source: Annual Congress 2008 - Clinical utility of exhaled nitric oxide measurement Year: 2008 Effect of once-daily inhaled glucocorticosteroid administration on exhaled nitric oxide in controlled asthma patients Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Concentration of nitric oxide in exhaled air (eNO) in patients with sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 Exhaled nitric oxide (FENO) in the assessment of the safety of allergen immunotherapy (SIT) in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 209s Year: 2006 Effect of systemic and extra-fine particle inhaled corticosteroids on corrected alveolar nitric oxide (CANO) in COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011 The effect of inhaled corticosteroid therapy on exhaled nitric oxide and exhaled hydrogen peroxide in asthma patients Source: Annual Congress 2006 - Monitoring airway inflammation – exhaled markers vs induced sputum Year: 2006 Fractional exhaled nitric oxide (FeNO) for an early diagnosis of asthma Source: Eur Respir J 2006; 28: Suppl. 50, 677s Year: 2006 The relationship between exhaled nitric oxide and compliance/adherence in patients with bronchial asthma using inhaled corticosteroids Source: Annual Congress 2012 - Clinical and diagnostic markers and management of paediatric allergic diseases Year: 2012 Non-adherence to inhaled corticosteroid therapy as an explanation for persistently elevated exhaled nitric oxide levels in patients with asthma: Effect of directly observed therapy with inhaled corticosteroids (DOT-ICS) Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015